论文部分内容阅读
血液透析(HD)治疗是终末期肾病的重要治疗方法之一,其心血管并发症的发生较正常人群明显升高,占病死原因的50%以上,而左心室肥厚(LVH)是主要的心脏病变,占心血管病变的50%~80%[1]。维持性血液透析3个月以上的患者普遍存在左卡尼汀不足,其缺乏可加重营养不良、血脂异常、贫血、胰岛素抵抗和葡萄糖不耐受、肌无力和肌病,也可导致透析患者出现与透析相关的肌肉抽搐、低血压和心律失常。有报道称,左卡尼汀治疗可以改善心功能不全,尤其是合并心脏收缩
Hemodialysis (HD) is one of the most important treatments for end-stage renal disease. Cardiovascular complications are significantly higher than the normal population, accounting for more than 50% of the causes of death, whereas left ventricular hypertrophy (LVH) is the major heart Lesions, accounting for 50% to 80% of cardiovascular disease [1]. Patients with maintenance hemodialysis for more than 3 months are generally experiencing inadequate levocarnitine and their lack of aggravating malnutrition, dyslipidemia, anemia, insulin resistance and glucose intolerance, muscle weakness and myopathy may also lead to dialysis patients Dialysis-related muscle twitching, hypotension and arrhythmia. It has been reported that levocarnitine treatment can improve cardiac insufficiency, especially with systolic